Lansoprazole induces sensitivity to suboptimal doses of paclitaxel in human melanoma

Tommaso Azzarito; Giulietta Venturi; Albino Cesolini; Stefano Fais

doi:10.1016/j.canlet.2014.10.017

journal article Jan 01, 2015

Lansoprazole induces sensitivity to suboptimal doses of paclitaxel in human melanoma

Tommaso Azzarito Giulietta Venturi

Albino Cesolini Stefano Fais

Cancer Letters Vol. 356 No. 2 pp. 697-703 · Elsevier BV

View at Publisher Save 10.1016/j.canlet.2014.10.017

Topics

No keywords indexed for this article. Browse by subject →

References

51

[1]

Jemal "Cancer statistics, 2010" CA Cancer J. Clin (2010) 10.3322/caac.20073

[2]

Bandarchi "From melanocyte to metastatic malignant melanoma" Dermatol. Res. Pract (2010) 10.1155/2010/583748

[3]

Bristow "Melanoma-related mortality and productivity losses in the USA, 1990–2008" Melanoma Res (2013) 10.1097/cmr.0b013e328361926c

[4]

Bhatia "Treatment of metastatic melanoma: an overview" Oncology (Williston Park) (2009)

[5]

Chen "Involvement of ABC transporters in melanogenesis and the development of multidrug resistance of melanoma" Pigment Cell. Melanoma Res (2009) 10.1111/j.1755-148x.2009.00630.x

[6]

Rass "Treatment of melanoma and nonmelanoma skin cancer" Adv. Exp. Med. Biol (2008) 10.1007/978-0-387-77574-6_23

[7]

De Milito "Tumor acidity, chemoresistance and proton pump inhibitors" Future Oncol (2005) 10.2217/14796694.1.6.779

[8]

Cairns "Regulation of cancer cell metabolism" Nat. Rev. Cancer (2011) 10.1038/nrc2981

[9]

Gatenby "Why do cancers have high aerobic glycolysis?" Nat. Rev. Cancer (2004) 10.1038/nrc1478

[10]

Harguindey "Proton transport inhibitors as potentially selective anticancer drugs" Anticancer Res (2009)

[11]

Fais "Proton pump inhibitor-induced tumour cell death by inhibition of a detoxification mechanism" J. Intern. Med (2010) 10.1111/j.1365-2796.2010.02225.x

[12]

De Milito "A rationale for the use of proton pump inhibitors as antineoplastic agents" Curr. Pharm. Des (2012) 10.2174/138161212799504911

[13]

Olbe "A proton-pump inhibitor expedition: the case histories of omeprazole and esomeprazole" Nat. Rev. Drug Discov (2003) 10.1038/nrd1010

[14]

Luciani "Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs" J. Natl. Cancer Inst (2004) 10.1093/jnci/djh305

[15]

Ferrari "Proton pump inhibitor chemosensitization in human osteosarcoma: from the bench to the patients’ bed" J. Transl. Med (2013) 10.1186/1479-5876-11-268

[16]

De Milito "Proton pump inhibitors induce apoptosis of human B-cell tumors through a caspase-independent mechanism involving reactive oxygen species" Cancer Res (2007) 10.1158/0008-5472.can-06-4095

[17]

De Milito "pH-dependent antitumor activity of proton pump inhibitors against human melanoma is mediated by inhibition of tumor acidity" Int. J. Cancer (2010) 10.1002/ijc.25009

[18]

Marino "Proton pump inhibition induces autophagy as a survival mechanism following oxidative stress in human melanoma cells" Cell. Death Dis (2010) 10.1038/cddis.2010.67

[19]

Udelnow "Omeprazole inhibits proliferation and modulates autophagy in pancreatic cancer cells" PLoS ONE (2011) 10.1371/journal.pone.0020143

[20]

Chen "Effects and mechanisms of proton pump inhibitors as a novel chemosensitizer on human gastric adenocarcinoma (SGC7901) cells" Cell Biol. Int (2009) 10.1016/j.cellbi.2009.05.004

[21]

Chen "Reversal effects of pantoprazole on multidrug resistance in human gastric adenocarcinoma cells by down-regulating the V-ATPases/mTOR/HIF-1alpha/P-gp and MRP1 signaling pathway in vitro and in vivo" J. Cell. Biochem (2012) 10.1002/jcb.24122

[22]

Shen "Effect of pantoprazole on human gastric adenocarcinoma SGC7901 cells through regulation of phosphoLRP6 expression in wnt/beta-catenin signaling" Oncol. Rep (2013) 10.3892/or.2013.2524

[23]

Yeo "Selective induction of apoptosis with proton pump inhibitor in gastric cancer cells" Clin. Cancer Res (2004) 10.1158/1078-0432.ccr-04-1065

[24]

Avnet "V-ATPase is a candidate therapeutic target for Ewing sarcoma" Biochim. Biophys. Acta (1832)

[25]

Perut "V-ATPase as an effective therapeutic target for sarcomas" Exp. Cell Res (2014) 10.1016/j.yexcr.2013.10.011

[26]

Zhang "Lansoprazole induces apoptosis of breast cancer cells through inhibition of intracellular proton extrusion" Biochem. Biophys. Res. Commun (2014) 10.1016/j.bbrc.2014.04.127

[27]

Spugnini "Lansoprazole as a rescue agent in chemoresistant tumors: a phase I/II study in companion animals with spontaneously occurring tumors" J. Transl. Med (2011) 10.1186/1479-5876-9-221

[28]

Spugnini "High dose lansoprazole combined with metronomic chemotherapy: a phase I/II study in companion animals with spontaneously occurring tumors" J. Transl. Med (2014) 10.1186/s12967-014-0225-y

[29]

Federici "Exosome release and low pH belong to a framework of resistance of human melanoma cells to cisplatin" PLoS ONE (2014) 10.1371/journal.pone.0088193

[30]

Wani "Plant antitumor agents. VI. the isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia" J. Am. Chem. Soc (1971) 10.1021/ja00738a045

[31]

Microtubules as a target for anticancer drugs

Mary Ann Jordan, Leslie Wilson

Nature Reviews Cancer 2004 10.1038/nrc1317

[32]

Legha "A phase II trial of taxol in metastatic melanoma" Cancer (1990) 10.1002/1097-0142(19900601)65:11<2478::aid-cncr2820651114>3.0.co;2-s

[33]

Kavallaris "Potential mechanisms of resistance to microtubule inhibitors" Semin. Oncol (2008) 10.1053/j.seminoncol.2008.01.006

[34]

Cree "Heterogeneity of chemosensitivity of metastatic cutaneous melanoma" Anticancer Drugs (1999) 10.1097/00001813-199906000-00002

[35]

Kretzer "Drug-targeting in combined cancer chemotherapy: tumor growth inhibition in mice by association of paclitaxel and etoposide with a cholesterol-rich nanoemulsion" Cell. Oncol. (Dordr) (2012) 10.1007/s13402-012-0104-6

[36]

Zimpfer-Rechner "Randomized phase II study of weekly paclitaxel versus paclitaxel and carboplatin as second-line therapy in disseminated melanoma: a multicentre trial of the dermatologic co-operative oncology group (DeCOG)" Melanoma Res (2003) 10.1097/00008390-200310000-00012

[37]

Vukovic "Influence of low pH on cytotoxicity of paclitaxel, mitoxantrone and topotecan" Br. J. Cancer (1997) 10.1038/bjc.1997.201

[38]

Reshkin "Paclitaxel induces apoptosis via protein kinase A- and p38 mitogen-activated protein-dependent inhibition of the Na+/H+ exchanger (NHE) NHE isoform 1 in human breast cancer cells" Clin. Cancer Res (2003)

[39]

Xiaodong "The growth and metastasis of human hepatocellular carcinoma xenografts are inhibited by small interfering RNA targeting to the subunit ATP6L of proton pump" Cancer Res (2005) 10.1158/0008-5472.can-04-3822

[40]

Ohkuma "Fluorescence probe measurement of the intralysosomal pH in living cells and the perturbation of pH by various agents" Proc. Natl. Acad. Sci. U.S.A. (1978) 10.1073/pnas.75.7.3327

[41]

Seo "Continuous fluorometric measurement of intracellular pH and Ca2+ in perfused salivary gland and pancreas" Pflugers Arch (1994) 10.1007/bf00374673

[42]

Morton "Guidelines on the recognition of pain, distress and discomfort in experimental animals and a hypothesis for assessment" Vet. Rec (1985) 10.1136/vr.116.16.431

[43]

Mouawad "Treatment for metastatic malignant melanoma: old drugs and new strategies" Crit. Rev. Oncol. Hematol (2010) 10.1016/j.critrevonc.2009.08.005

[44]

Fais "Targeting vacuolar H+-ATPases as a new strategy against cancer" Cancer Res (2007) 10.1158/0008-5472.can-07-1805

[45]

Bedikian "Phase II evaluation of paclitaxel by short intravenous infusion in metastatic melanoma" Melanoma Res (2004) 10.1097/00008390-200402000-00010

[46]

Hauschild "Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma" J. Clin. Oncol (2009) 10.1200/jco.2007.15.7636

[47]

Tavares-Valente "Cancer cell bioenergetics and pH regulation influence breast cancer cell resistance to paclitaxel and doxorubicin" J. Bioenerg. Biomembr (2013) 10.1007/s10863-013-9519-7

[48]

Calcinotto "Modulation of microenvironment acidity reverses anergy in human and murine tumor-infiltrating T lymphocytes" Cancer Res (2012) 10.1158/0008-5472.can-11-1272

[49]

Lu "PEG-derivatized embelin as a nanomicellar carrier for delivery of paclitaxel to breast and prostate cancers" Biomaterials (2013) 10.1016/j.biomaterials.2012.10.073

[50]

Zhang "Anti-tumor efficacy and biodistribution of intravenous polymeric micellar paclitaxel" Anticancer Drugs (1997) 10.1097/00001813-199708000-00008

Showing 50 of 51 references

Cited By

81

Influence of the proton pump inhibitor lansoprazole on distribution and activity of doxorubicin in solid tumors

Man Yu, Carol Lee · 2015

Cancer Science

Metrics

81

Citations

51

References

Details

Published: Jan 01, 2015
Vol/Issue: 356(2)
Pages: 697-703
License: View

Authors

These authors contributed equally to this article and share first authorship; Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy

5Department of Drug Research and Evaluation, Section of Pharmacogenetic, Drug Resistance and Experimental Therapeutics, Istituto Superiore di Sanità, Rome, Italy

Cite This Article

Tommaso Azzarito, Giulietta Venturi, Albino Cesolini, et al. (2015). Lansoprazole induces sensitivity to suboptimal doses of paclitaxel in human melanoma. Cancer Letters, 356(2), 697-703. https://doi.org/10.1016/j.canlet.2014.10.017

Lansoprazole induces sensitivity to suboptimal doses of paclitaxel in human melanoma

You May Also Like